Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Targeted Drug for Melanoma Shows Promise in Early Clinical Testing
(Posted: 09/24/2010) - The vast majority of patients with advanced melanoma who received an experimental targeted drug called PLX4032 responded to the treatment in a phase I clinical trial, researchers reported in the August 26, 2010, New England Journal of Medicine.
- For Women with BRCA Mutations, Prophylactic Surgery Reduces Cancer Risk
(Posted: 09/23/2010) - Prophylactic surgery to remove the breasts and ovaries is an effective way to reduce the risk of breast and ovarian cancer among women with inherited mutations in the BRCA1 or BRCA2 genes, according to one of the largest prospective studies on the subject to date.
- Palliative Care Improves Survival, Quality of Life in Advanced Lung Cancer
(Posted: 09/23/2010) - Patients with advanced lung cancer who received early palliative care experienced longer median survival than those who only received palliative care near death, according to results of a randomized clinical trial published August 19, 2010, in the New England Journal of Medicine.
- Less-intensive Treatment Regimen Effective against Multiple Myeloma
(Posted: 09/23/2010) - Treating patients who have multiple myeloma with less-intensive dosing of bortezomib (Velcade®) reduced toxic side effects without making the treatment less effective, Spanish researchers reported online August 23, 2010, in The Lancet Oncology.
- Gefitinib Improves Progression-free Survival for Metastatic Lung Cancers with EGFR Mutations
(Posted: 08/12/2010) - Patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC) who received gefitinib (Iressa) had significantly higher response rates and longer progression-free survival compared with patients who received carboplatin plus paclitaxel, according to results of a phase III trial conducted in Japan.